OpenEvidence vs UpToDate
Both answer the same clinical question at the same moment. The split is what the answer is grounded in and who pays for it. If your failure mode is a fluent answer built on real citations with faulty reasoning behind them, the independent literature documents precisely that in OpenEvidence: accurate citations, interpretive errors. If your failure mode is an authoritative answer inheriting the blind spots of a single editorial tradition, that is UpToDate's structural exposure, and it publishes no evaluation output to bound it. OpenEvidence is free, funded by pharmaceutical and device advertising, and United States only since April 2026. UpToDate is subscription funded, openly priced at the individual tier, and sold in more than thirty countries. Start with UpToDate if oversight design decides it, OpenEvidence if literature breadth and cost do.
- The independent evidence base is deeper here than almost anywhere in this index, and the vendor commissioned none of it. A systematic review following PRISMA covering eleven studies published between 2024 and 2026 found the platform generates evidence supported answers and avoids fabricated citations, performing strongest on structured guideline based questions. UpToDate has no published benchmark or evaluation result of any kind for Expert AI, despite having published a framework for evaluating clinical AI.
- Grounding is breadth, and it is current. More than 300 medical journals plus FDA and CDC sources, under official AI partnerships with the New England Journal of Medicine, with JAMA and its eleven specialty journals, with Cochrane Systematic Reviews and with the NCCN, alongside content agreements across more than a dozen specialty societies. If the question turns on evidence published in the last eighteen months, this is the corpus more likely to hold it.
- Security and compliance disclosure is materially stronger and independently attested. SOC 2 Type II for the Security trust services category verified through a public trust centre, an annual external penetration test, ten named security policies reviewed annually, a vulnerability disclosure programme with a bug bounty, and cloud providers named specifically. This index located no SOC 2, no attestation and no trust centre for UpToDate.
- The oversight architecture is the best of any generative clinical product graded in this index. Every answer opens with a stated assumptions block naming what the system took for granted about the patient, and inline nudges ask the clinician to supply context the system lacks, such as comorbidities or ICU status. It names the gap rather than papering over it. OpenEvidence publishes no abstention behaviour, uncertainty signal or equivalent mechanism.
- No conflict of interest sits between the clinician and the answer, because the reader pays. OpenEvidence is funded by pharmaceutical and medical device advertising, and while its advertising policy states advertisers cannot influence answers, the reverse direction is unpoliced: reporting on its privacy policy describes engagement with particular clinical topics being used to target advertising by specialty and interest. Ads may not shape the answer, but the questions shape the ads.
- It is still available in Europe, and the institutional compliance path is more conventional. OpenEvidence terminated access across the European Union and the United Kingdom at the end of April 2026, citing regulatory uncertainty including the EU AI Act. UpToDate sells in more than thirty countries, though its Expert AI layer is itself bounded to individual subscribers in the United States and Canada, so the contrast is withdrawal against limited rollout.
Side-by-Side
| Axis | O OpenEvidence |
U UpToDate |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
The retrieval gaps on these two records are not symmetric and that shapes the grid. UpToDate's HIPAA and security axes are Not Rated because no attestation was located in the material read, not because none exists: a listed multinational integrated into Epic across thirty countries will hold documentation this index did not find. Its evidence grade carries the same caveat, since an older peer reviewed outcomes literature for the underlying content product exists and was not assessed. On the OpenEvidence side, the accuracy figures now circulating in competitor marketing, 34 percent for Quick Consult and 41 percent for Deep Consult on subspecialty board questions, come from a November 2025 medRxiv preprint that states plainly it has not been peer reviewed, and on the same dataset eleven large language models scored between 14 and 46 percent, so those numbers sit inside the established band rather than beneath it. OpenEvidence's own material contradicts itself on protected health information: the security page invites covered entities to transmit it under a Business Associate Agreement while the About page states user inputs are not covered by HIPAA. Neither vendor publishes enterprise pricing, which is the tier a health system actually buys. Adoption, scale and consultation volume figures on both sides are vendor reported and unaudited.